{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:58:11Z","timestamp":1791619091619,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001502","name":"Blue Cross Blue Shield of Michigan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001502","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacadv.2025.101714","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T14:23:57Z","timestamp":1745591037000},"page":"101714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for\u00a0Atrial Fibrillation and\/or Venous\u00a0Thromboembolism"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-386X","authenticated-orcid":false,"given":"Jordan K.","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Errickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina","family":"Chipalkatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Haymart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kaatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Krol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman L.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6532-8440","authenticated-orcid":false,"given":"Geoffrey D.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jacadv.2025.101714_bib1","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s11606-020-05904-0","article-title":"Oral anticoagulant utilization in the United States and United Kingdom","volume":"35","author":"Colacci","year":"2020","journal-title":"J\u00a0Gen Intern Med"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101714_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.4059","article-title":"Trends in the use of oral anticoagulants for adults with venous thromboembolism in the US, 2010-2020","volume":"6","author":"Iyer","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.jacadv.2025.101714_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician trends in prescribing direct oral anticoagulants for US medicare beneficiaries","volume":"4","author":"Wheelock","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"19","key":"10.1016\/j.jacadv.2025.101714_bib4","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101714_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacadv.2025.101714_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101714_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-015-2566-x","article-title":"How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation","volume":"95","author":"Schaefer","year":"2016","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101714_bib8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jacadv.2025.101714_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.jacadv.2025.101714_bib10","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.jacadv.2025.101714_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Investigators","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101714_bib12","article-title":"Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism","volume":"4","author":"Li","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101714_bib13","article-title":"Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation","volume":"3","author":"Bruins Slot","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jacadv.2025.101714_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamainternmed.2021.1197","article-title":"Adverse events associated with the addition of aspirin to direct oral anticoagulant therapy without a clear indication","volume":"181","author":"Schaefer","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101714_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101714_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"10.1016\/j.jacadv.2025.101714_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2025.101714_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"issue":"467","key":"10.1016\/j.jacadv.2025.101714_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1198\/016214504000000647","article-title":"Full matching in an observational study of coaching for the SAT","volume":"99","author":"Hansen","year":"2004","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"30","key":"10.1016\/j.jacadv.2025.101714_bib20","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1002\/sim.6602","article-title":"Optimal full matching for survival outcomes: a method that merits more widespread use","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.jacadv.2025.101714_bib21","series-title":"Springer Series in Statistics","article-title":"Design of observational studies","author":"Rosenbaum","year":"2020"},{"issue":"3","key":"10.1016\/j.jacadv.2025.101714_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101714_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M21-0717","article-title":"Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.jacadv.2025.101714_bib24","doi-asserted-by":"crossref","first-page":"910","DOI":"10.7326\/M20-6194","article-title":"Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population-based cohort study","volume":"174","author":"Dawwas","year":"2021","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101714_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221500","article-title":"Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: a nationwide pharmacoepidemiological study","volume":"14","author":"Kjerpeseth","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101714_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12872-019-1116-1","article-title":"Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naive non-valvular atrial fibrillation patients in the US Department of defense population","volume":"19","author":"Gupta","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101714_bib27","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/jgs.15956","article-title":"Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients","volume":"67","author":"Deitelzweig","year":"2019","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101714_bib28","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1080\/03007995.2017.1345729","article-title":"Risk of stroke\/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population","volume":"33","author":"Amin","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101714_bib29","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","article-title":"Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"48","author":"Ntaios","year":"2017","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.jacadv.2025.101714_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144856","article-title":"Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and Network meta-analysis","volume":"10","author":"Cohen","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jacadv.2025.101714_bib31","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1182\/bloodadvances.2022009099","article-title":"Comparison of the effectiveness and safety of direct oral anticoagulants: a nationwide propensity score-weighted study","volume":"7","author":"Ingason","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jacadv.2025.101714_bib32","first-page":"414","article-title":"Clinical and safety outcomes associated with extended treatment of venous thromboembolism: a Network meta-analysis","volume":"9","author":"Liu","year":"2022","journal-title":"J\u00a0Cardiovasc Dev Dis"},{"key":"10.1016\/j.jacadv.2025.101714_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619898764","article-title":"A\u00a0systematic review of network meta-analyses and real-world evidence comparing apixaban and rivaroxaban in nonvalvular atrial fibrillation","volume":"26","author":"Hill","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jacadv.2025.101714_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2018.03.047","article-title":"Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation","volume":"268","author":"Andersson","year":"2018","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.jacadv.2025.101714_bib35","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.mayocp.2018.09.022","article-title":"Apixaban and rivaroxaban in patients with acute venous thromboembolism","volume":"94","author":"Bott-Kitslaar","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.jacadv.2025.101714_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/ehjcvp\/pvy021","article-title":"Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study","volume":"4","author":"Sindet-Pedersen","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101714_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2018.04.036","article-title":"Risk of myocardial infarction in anticoagulated patients with atrial fibrillation","volume":"72","author":"Lee","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacadv.2025.101714_bib38","article-title":"Comparison of direct oral anticoagulants and warfarin in the prevention of stroke in patients with valvular heart disease: a meta-analysis","volume":"14","author":"Batool","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jacadv.2025.101714_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jacadv.2025.101714_bib40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25001310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25001310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:38:20Z","timestamp":1748468300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25001310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2772963X25001310"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101714","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for\u00a0Atrial Fibrillation and\/or Venous\u00a0Thromboembolism","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101714","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101714"}}